Fig. 3: Longitudinal trend of WBC, NLR, neutrophils and lymphocytes in patients treated with Ropeginterferon (Ropeg) or phlebotomy (PHL), including subgroups with elevated baseline values (Low-PV database). | Blood Cancer Journal

Fig. 3: Longitudinal trend of WBC, NLR, neutrophils and lymphocytes in patients treated with Ropeginterferon (Ropeg) or phlebotomy (PHL), including subgroups with elevated baseline values (Low-PV database).

From: Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera

Fig. 3

12-months trends of WBC (A), NLR (B), neutrophils (C), and lymphocytes (D) by treatment received in Low-PV database. The trend for the whole cohort and a focus on the subgroup of patients with high baseline values (above the median value) are reported in each panel. Global differences between the two treatments and differences over time were evaluated by a linear mixed-effect model with treatment, time and treatment-time interaction as fixed effects and patient as random intercept. *p-value for the main effect of treatment; **p-values for treatment-time interaction: a significant p-value indicates that the trend of each biomarker over time is different in the two arms, suggesting that the treatment affects how the parameter changes over time.

Back to article page